• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PACS Group Announces Appointment of Evelyn Dilsaver to Serve as Independent Board Director

    5/13/24 7:31:00 PM ET
    $HQY
    $QDEL
    $TPX
    Real Estate
    Real Estate
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $HQY alert in real time by email

    PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company") announced today that Evelyn Dilsaver has been appointed to serve as a member of its Board of Directors. "We're thrilled to have Evelyn join our board," said Jason Murray, PACS Chairman and CEO. "She has great experience as an accounting and finance professional, not to mention her work on the boards of several other public companies. She'll bring added perspective and expertise to the board as we work to guide PACS going forward."

    "I'm excited to join the PACS Board and assist the company in continuing its mission to provide quality skilled nursing care. I look forward to great things ahead for the company," added Ms. Dilsaver.

    Ms. Dilsaver also serves on the boards of directors of Tempur Sealy International (NYSE:TPX), HealthEquity, Inc. (NASDAQ:HQY) and QuidelOrtho (NASDAQ:QDEL). Ms. Dilsaver was President and Chief Executive Officer of Charles Schwab Investment Management from July 2004 until September 2007. Prior to that, she held various senior management positions with The Charles Schwab Corporation. Ms. Dilsaver is a certified public accountant and holds a B.S. degree in accounting from California State University-Hayward.

    Ms. Dilsaver is an independent director under applicable NYSE and SEC rules. Her appointment now makes the PACS Board of Directors majority independent. Ms. Dilsaver's committee appointments will be considered at a later date.

    About PACS Group

    PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate over 200 post-acute care facilities across nine states serving over 20,000 patients daily.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240513694766/en/

    Get the next $HQY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HQY
    $QDEL
    $TPX

    CompanyDatePrice TargetRatingAnalyst
    HealthEquity Inc.
    $HQY
    1/9/2026$89.00Neutral → Sell
    Goldman
    HealthEquity Inc.
    $HQY
    12/9/2025$118.00Overweight
    Barclays
    HealthEquity Inc.
    $HQY
    11/13/2025$100.00Market Perform
    BMO Capital Markets
    QuidelOrtho Corporation
    $QDEL
    10/7/2025$33.00Buy → Neutral
    Citigroup
    HealthEquity Inc.
    $HQY
    5/22/2025$105.00 → $112.00Outperform
    RBC Capital Mkts
    QuidelOrtho Corporation
    $QDEL
    5/8/2025$44.00Hold → Buy
    Jefferies
    HealthEquity Inc.
    $HQY
    3/25/2025$120.00 → $115.00Outperform → Strong Buy
    Raymond James
    Tempur Sealy International Inc.
    $TPX
    2/5/2025Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $HQY
    $QDEL
    $TPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Hanson Bryan Michael

    3 - QuidelOrtho Corp (0001906324) (Issuer)

    3/24/26 4:40:52 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4/A - QuidelOrtho Corp (0001906324) (Issuer)

    2/19/26 4:18:05 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Strobeck Matthew bought $239,586 worth of shares (10,000 units at $23.96), increasing direct ownership by 56% to 27,775 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 4:20:08 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

    SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.

    3/24/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HealthEquity Reports Record Revenue, Earnings and New HSAs From Sales for Fourth Quarter and Year Ended January 31, 2026, Resulting in Raised Fiscal 2027 Outlook

    Highlights of the fiscal year include: Revenue increased 9% to $1.31 billion.Net income increased 123% to $215.2 million, and net income margin increased to 16% from 8% last year.Net income per diluted share rose to $2.46 from $1.09 one year ago, and non-GAAP net income per diluted share increased 28% to $4.00.Adjusted EBITDA increased 20% to $566.0 million, and Adjusted EBITDA margin increased to 43% from 39% last year.Total HSA Assets grew 14% to $36.5 billion.Returned $301.7 million to shareholders through stock repurchases.Further reduced HSA cash repricing risk with a cumulative $2.35 billion 5-year Treasury bond hedge at 3.92%. Highlights of the fourth quarter include: Revenue incre

    3/17/26 4:01:00 PM ET
    $HQY
    Real Estate

    Phreesia Appoints Jon Kessler to Board of Directors

    Industry Veteran Brings Track Record of Technology-Driven Growth and Value Creation Edward L. Cahill and Michael Weintraub to Retire at 2026 Annual Meeting of Stockholders Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") today announced that it has appointed Jon Kessler to its Board, effective April 6, 2026. In addition, Edward L. Cahill and Michael Weintraub have informed the Board that they will retire from the Board, effective at the 2026 Annual Meeting. Mr. Kessler is an experienced public company CEO and director who will bring valuable expertise to the Phreesia Board. As founder, Chairman and CEO of WageWorks and most recently President and CEO of HealthEquity (NASDAQ:HQY

    2/23/26 4:03:00 PM ET
    $HQY
    $PHR
    Real Estate

    $HQY
    $QDEL
    $TPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HealthEquity downgraded by Goldman with a new price target

    Goldman downgraded HealthEquity from Neutral to Sell and set a new price target of $89.00

    1/9/26 8:49:40 AM ET
    $HQY
    Real Estate

    Barclays initiated coverage on HealthEquity with a new price target

    Barclays initiated coverage of HealthEquity with a rating of Overweight and set a new price target of $118.00

    12/9/25 8:49:54 AM ET
    $HQY
    Real Estate

    BMO Capital Markets initiated coverage on HealthEquity with a new price target

    BMO Capital Markets initiated coverage of HealthEquity with a rating of Market Perform and set a new price target of $100.00

    11/13/25 9:13:59 AM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    SEC Filings

    View All

    QuidelOrtho Corporation filed SEC Form 8-K: Regulation FD Disclosure

    8-K - QuidelOrtho Corp (0001906324) (Filer)

    3/24/26 7:00:12 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-K filed by HealthEquity Inc.

    10-K - HEALTHEQUITY, INC. (0001428336) (Filer)

    3/17/26 4:03:59 PM ET
    $HQY
    Real Estate

    HealthEquity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HEALTHEQUITY, INC. (0001428336) (Filer)

    3/17/26 4:02:34 PM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4/A - QuidelOrtho Corp (0001906324) (Issuer)

    2/19/26 4:18:05 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Strobeck Matthew bought $239,586 worth of shares (10,000 units at $23.96), increasing direct ownership by 56% to 27,775 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 4:20:08 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 12:44:31 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Leadership Updates

    Live Leadership Updates

    View All

    Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

    SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.

    3/24/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HealthEquity Strengthens Executive Leadership Team with Strategic Appointments to Drive Growth and Innovation

    DRAPER, Utah, Sept. 25, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY), the nation's largest Health Savings Accounts (HSAs) and consumer-directed benefits administrator, today announced the appointment of new senior executives to accelerate the company's strategic vision and capitalize on expanding market opportunities. Mukund Ramachandran joins as Chief Marketing Officer and Garett Kitch as Senior Vice President of Client Sales & Relationship Management, effective September 29, 2025. The appointments come as HealthEquity continues to execute against record financial performance, alongside the largest HSA eligibility expansion in 20 years following recent federal legislation.

    9/25/25 9:00:00 AM ET
    $HQY
    Real Estate

    QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

    SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal

    8/19/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Financials

    Live finance-specific insights

    View All

    HealthEquity Reports Record Revenue, Earnings and New HSAs From Sales for Fourth Quarter and Year Ended January 31, 2026, Resulting in Raised Fiscal 2027 Outlook

    Highlights of the fiscal year include: Revenue increased 9% to $1.31 billion.Net income increased 123% to $215.2 million, and net income margin increased to 16% from 8% last year.Net income per diluted share rose to $2.46 from $1.09 one year ago, and non-GAAP net income per diluted share increased 28% to $4.00.Adjusted EBITDA increased 20% to $566.0 million, and Adjusted EBITDA margin increased to 43% from 39% last year.Total HSA Assets grew 14% to $36.5 billion.Returned $301.7 million to shareholders through stock repurchases.Further reduced HSA cash repricing risk with a cumulative $2.35 billion 5-year Treasury bond hedge at 3.92%. Highlights of the fourth quarter include: Revenue incre

    3/17/26 4:01:00 PM ET
    $HQY
    Real Estate

    QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results

    ― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagno

    2/11/26 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results

    SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the fourth quarter and full year 2025 ended December 28, 2025, after the market close on Wednesday, February 11, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "

    1/21/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    11/14/24 1:28:35 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care